Objective
Tuberculosis is one of the most worrying Global and Public Health problems in the present day and causes a major economic and social burden, which can significantly drain a society’s resources. In 2015, 10.4 million people fell ill with tuberculosis and 1.8 million died from the disease. In addition, an estimated 480000 people developed multidrug-resistant tuberculosis. The development of new drugs and new therapeutic regimens effective against drug susceptible and drug resistant tuberculosis is one of the greatest challenges in the way of tuberculosis control. Conventional drug discovery strategies are usually costly and time-consuming and, frequently, with low rates of success. This project aims to develop a new paradigm for tuberculosis drug development, using the drug repurposing strategy (to find new uses for already approved drugs) coupled with an in silico chemogenomics method. The focus will be targeting energy metabolism, particularly the oxidative phosphorylation, a novel target pathway in tuberculosis drug discovery. This research project has the potential to greatly benefit tuberculosis drug discovery by finding new drugs for a largely unexplored pathway and by introducing a new approach that can increase the probability of identifying effective drugs and decrease the bottlenecks of the conventional drug discovery approach, saving both time and money. Since tuberculosis has a high social and economic impact, this project aims not only to contribute to scientific and academic knowledge in this field, but also to increase public awareness on tuberculosis drug resistance and the need for new drugs by using several outreach activities. Finally, searching for new effective drugs that can tackle the problem of drug resistance and reduce the costs of drug treatment contributes to the decrease of social impact and economic burden of this disease and is in line with the goals of the World Health Organization “End TB” strategy.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences basic medicine pharmacology and pharmacy drug discovery
- medical and health sciences health sciences public health
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance
- medical and health sciences clinical medicine pneumology tuberculosis
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.3. - EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.3.2. - Nurturing excellence by means of cross-border and cross-sector mobility
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
MSCA-IF-EF-CAR - CAR – Career Restart panel
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-MSCA-IF-2017
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1099 085 Lisboa
Portugal
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.